| ORIGINAL ARTICLE |
|
| Year : 2020 | Volume
: 9
| Issue : 8 | Page : 4107-4111 |
|
|
Screening for cervical dysplasia and reproductive tract infections in Kerala, India: A multicentric study
Jeremiah Jacob Tom1, Clint Vaz2, Catherin Nisha1
1 Department of Community Medicine, Amala Institute of Medical Sciences, Thrissur, Kerala, India
2 Department of Clinical Immunology and Rheumatology, Amala Institute of Medical Sciences; Current status: Chief Medical Officer, St. Joseph's Hospital, Thrissur, Kerala, India
Correspondence Address:
Dr. Catherin Nisha
Department of Community Medicine, Amala Institute of Medical Sciences, Amala Nagar, Thrissur, Kerala - 680555
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jfmpc.jfmpc_514_20
|
|
|
Background: Cancer of the uterine cervix is estimated to the second most frequently occurring malignancy among females in India. Cancer mortality profile in India estimates that 20.7% of cancer deaths in females are cervical cancer. This well elucidates the fatal aspect of the disease and the need for early detection. Aims: To screen for cervical dysplasias and reproductive tract infections in various parts of Kerala, India, and determine its associated factors. Methods and Methodology: This was a descriptive cross-sectional study conducted in various parts of Kerala, India. This study included an interview schedule to collect data and the procedures included per speculum examination along with a Pap smear test. Results: A total of 199 women were screened with mean age of 45.87 ± 9.84 years. Of these, 13.5% showed inflammatory smears, 1% showed infective pathology and 1.5% showed pre-malignant lesions. Conclusion: The increased rates of inflammation and infection show its importance in public health. Similar community-based screening as well as routine screening by physicians/gynaecologists is recommended for early detection of cervical cancer and reproductive tract infections. Community education among the population proves to be an important factor; especially regarding HPV vaccination.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
